Medical Research: Getting to grips with muscular dystrophy
Nature Communications
March 6, 2013
A combined stem cell and gene therapy has been used to successfully treat mice with muscular dystrophy, reports a paper published in Nature Communications this week. The study, which uses genetically corrected induced pluripotent stem (iPS) cells derived from sick mice, might represent an important step towards the treatment of muscular dystrophies.
Duchenne muscular dystrophy is a progressive and incurable neuromuscular disease caused by mutations in the dystrophin gene. Rita Perlingeiro and her team took fibroblasts from mice with a severe form of muscular dystrophy and converted them into iPS cells. They then corrected the genetic defect, differentiated the cells into muscle precursor cells, and transplanted them back into the muscle of the respective donor mice. They found that the genetically corrected cells formed functional muscle fibres and mice showed improvements in muscle strength.
doi: 10.1038/ncomms2550
Research highlights
-
Jan 13
Genetics: Correcting for genetic associations between alcohol and diseaseNature Communications
-
Dec 23
Biomedical engineering: Tiny device goes with the (blood) flowNature Communications
-
Dec 21
Epidemiology: Underdetection of COVID-19 after the first lockdown in FranceNature
-
Dec 18
Geology: Alpine summits may have been ice-free during life of Tyrolean IcemanScientific Reports
-
Dec 17
Epidemiology: Mapping gaps in measles vaccination coverageNature
-
Dec 17
Neuroscience: When you’re smiling, the whole world smiles with youNature
